Articles from Cell BioEngines, Inc.

Cell BioEngines Joins Center for Engineering and Precision Medicine (CEPM), Expands Relationship with Mount Sinai

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a New York, USA-based company researching stem cells in order to develop new cell therapies unlocked $1.75 million additional funds from SOSV and the Partnership Fund through the new therapeutics seed track, available for therapeutics start-ups. In addition, Cell BioEngines raised $0.25 million from Empire State Development’s NY Ventures, the state’s venture capital arm through the Pre-Seed and Seed Matching Fund Program.

Clinical-Stage Biotech to Unveil Off-the-Shelf Non-Gene Modified Hematopoietic Stem Cells and Its Derived Immune Cell Therapies

Cell BioEngines, Inc moves to Manhattan, New York, to leverage the city’s focus and strategic investment in biotech

Cell BioEngines to Leverage Miltenyi’s Expertise and Proven Platforms to Develop and Manufacture Hematopoietic Stem Cell Transplantation (HSCT) Product

Small molecule-mediated expansion of engraftable cord-blood derived hematopoietic stem cells (HSC) to address donor availability for allogenic hematopoietic stem cell transplant

BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors, today announced that it has entered into an exclusive license agreement with Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”), in New York, NY for the development and worldwide commercialization rights relating to intellectual property for differentiating most potent immune cell from stem cells and large-scale manufacturing. Under the agreement, Cell BioEngines will utilize Icahn Mount Sinai’s technology platform to develop discrete immune cell-based therapies, such as subtypes of dendritic cells (DC), NK cells, and macrophages, previously inaccessible to cancer patients.